Journal Article Summary
The article investigates how body mass index (BMI) affects the effectiveness and safety of two antiplatelet medications, ticagrelor and clopidogrel, in patients who have experienced a minor stroke or transient ischemic attack (TIA). This topic is significant because obesity is a global health issue that increases the risk of stroke, and understanding how BMI influences medication response can help optimize treatment for these patients. The study specifically focuses on individuals who carry a genetic variant affecting drug metabolism, which may alter their response to these medications.
In this study, researchers analyzed data from a large clinical trial involving over 6,400 patients with minor stroke or TIA, categorizing them into obese and nonobese groups based on their BMI. They found that ticagrelor was more effective than clopidogrel in reducing the risk of stroke within 90 days for patients with obesity, while no significant difference was observed in the nonobese group. Additionally, the rates of severe or moderate bleeding were similar between the two medications, indicating that ticagrelor did not increase bleeding risk compared to clopidogrel.
However, the study has limitations, including the potential for type I errors due to its secondary analysis nature and the modest correlation between BMI and fat mass, suggesting that other measures of obesity could be relevant. Patients should consult with healthcare professionals about their individual risks and benefits when considering antiplatelet therapy, especially if they are obese or have a CYP2C19 loss-of-function allele. This discussion is crucial for making informed decisions about treatment options and managing stroke risk effectively.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Zhang Jia, Wang Anxin, Tian Xue, Meng Xia, Xie Xuewei, Jing Jing, Lin Jinxi, Wang Yilong, et al.. Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack. CMAJ : Canadian Medical Association Journal 2023. DOI: 10.1503/cmaj.230262. PMID: 37429630. PMCID: PMC10446134.
Featured Pill Pals Product
Clopidogrel 75 mg Tablets --- Generic For Plavix --- ScieGen
Clopidogrel 75 mg Tablets — Generic For Plavix — ScieGen is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
